Old Articles: <Older 7901-7910 Newer> |
|
The Motley Fool September 28, 2011 Alex Dumortier |
Edwards Lifesciences: Creating or Destroying Value? With shares trading at 33.2 times its earnings-per-share estimate for the next 12 months, the share buyback program looks like a poor use of shareholder capital at these prices. |
The Motley Fool September 27, 2011 Brian Orelli |
Promising Results, But It's Still Early Aeterna Zentaris' investors got a bit of good news yesterday while they wait for phase 3 data for the company's colorectal cancer drug perifosine. |
Registered Rep. September 26, 2011 Stan Luxenberg |
Despite Ill Winds, Health Stocks Look Healthy Health stock valuations look compelling, and many companies should report solid earnings growth. |
The Motley Fool September 26, 2011 Brian Orelli |
Closer to Approval, Now Can MELA Find Customers? The restrictions might be too much. The company has been fighting for years to gain Food and Drug Administration approval of its melanoma detection device, MelaFind. |
The Motley Fool September 23, 2011 Michael Olsen |
1 Special Stock Pick From an Outside View Don't fall prey to market myopia. We expect contract researchers -- like Charles River, Icon, and Pharmaceutical Product Development -- to benefit as pharmaceutical companies adopt an increasingly cost-conscious posture. |
The Motley Fool September 23, 2011 Brian Orelli |
Matching Supply and Demand Is Easier Said Than Done Pac Bio cuts its workforce due to lower-than-expected demand. |
The Motley Fool September 21, 2011 Brian Orelli |
Obesity-Drug Makers Stop Getting Bullied The drugs are still relative long shots being developed by companies that may have to raise more cash between now and an approval. |
The Motley Fool September 21, 2011 |
One Hot Stock to Avoid Our investing community's latest prime pick to avoid: MELA Sciences. |
The Motley Fool September 21, 2011 Luke Timmerman |
Orexigen Revives Obesity Drug After One More Go-Round With FDA Orexigen has new life. |
The Motley Fool September 21, 2011 Seth Jayson |
How Long Does It Take to Make a Buck at Merck? With quarterly CCC doing worse than average and the latest 12-month CCC coming in better, Merck gets a mixed review in this cash-conversion checkup. |
<Older 7901-7910 Newer> Return to current articles. |